Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90

FEBS Lett. 2008 Nov 26;582(28):3879-83. doi: 10.1016/j.febslet.2008.10.029. Epub 2008 Oct 26.

Abstract

The 90-kDa heat shock protein (HSP90) is a molecular chaperone that assists in the folding and assembly of proteins in the cytosol. We previously demonstrated that the antineoplastic reagent, cisplatin, inhibits the aggregation prevention activity of mammalian HSP90. We now show that cisplatin binds both the amino terminal and carboxyl terminal domains of the human HSP90 and differently affects these two domains. Cisplatin blocks the aggregation prevention activity of HSP90C, but not HSP90N. In contrast, cisplatin induces a conformational change in HSP90N, but not HSP90C. These results indicate that cisplatin modulates the HSP90 activities through two different mechanisms using the two distinct binding sites of the HSP90 molecule.

MeSH terms

  • Amino Acid Motifs
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Binding Sites / drug effects
  • Cisplatin / chemistry
  • Cisplatin / pharmacology*
  • HSP90 Heat-Shock Proteins / chemistry
  • HSP90 Heat-Shock Proteins / drug effects*
  • Humans
  • Protein Structure, Tertiary / drug effects

Substances

  • Antineoplastic Agents
  • HSP90 Heat-Shock Proteins
  • Cisplatin